Established a reliable biomarker in terms of postoperative adjuvant chemotherapy for pancreatic ductal adenocarcinoma

被引：0
|
作者：
Yamada, Daisaku [1 ]
Takeda, Yu [1 ]
Kobayashi, Shogo [1 ]
Sasaki, Kazuki [1 ]
Iwagami, Yoshifumi [1 ]
Tomimaru, Yoshito [1 ]
Noda, Takehiro [1 ]
Takahashi, Hidenori [1 ]
Doki, Yuichiro [1 ]
Eguchi, Hidetoshi [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3309
引用
收藏
页码：2138 / 2138
页数：1
相关论文
共 50 条
  • [1] Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma
    Leonhardt Carl S.
    Traub Benno
    Hackert Thilo
    Klaiber Ulla
    Strobel Oliver
    Büchler Markus W.
    Neoptolemos John P.
    Department of General
    Department of Surgery
    胰腺病学杂志（英文）, 2020, 03 (01) : 1 - 11
  • [2] MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma
    Takeda, Yu
    Yamada, Daisaku
    Kobayashi, Shogo
    Sasaki, Kazuki
    Iwagami, Yoshifumi
    Tomimaru, Yoshito
    Noda, Takehiro
    Takahashi, Hidenori
    Asaoka, Tadafumi
    Shimizu, Junzo
    Doki, Yuichiro
    Eguchi, Hidetoshi
    PLOS ONE, 2024, 19 (09):
  • [3] Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
    Matsumoto, Ippei
    Tanaka, Masaki
    Shirakawa, Sachiyo
    Shinzeki, Makoto
    Toyama, Hirochika
    Asari, Sadaki
    Goto, Tadahiro
    Yamashita, Hironori
    Ishida, Jun
    Ajiki, Tetsuo
    Fukumoto, Takumi
    Shimokawa, Mototsugu
    Ku, Yonson
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (07) : 2408 - 2415
  • [4] Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
    Ippei Matsumoto
    Masaki Tanaka
    Sachiyo Shirakawa
    Makoto Shinzeki
    Hirochika Toyama
    Sadaki Asari
    Tadahiro Goto
    Hironori Yamashita
    Jun Ishida
    Tetsuo Ajiki
    Takumi Fukumoto
    Mototsugu Shimokawa
    Yonson Ku
    Annals of Surgical Oncology, 2015, 22 : 2408 - 2415
  • [5] IS AGE A BARRIER TO RECEIVING ADJUVANT CHEMOTHERAPY FOR PANCREATIC DUCTAL ADENOCARCINOMA?
    Malik, A. K.
    Lamarca, A.
    Siriwardena, A. K.
    O'Reilly, D. A.
    Deshpande, R.
    Satyadas, T.
    Jamdar, S.
    Sheen, A. J.
    McNamara, M. G.
    Hubner, R. A.
    Valle, J. W.
    Carino, N. De Liguori
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 13 - 13
  • [6] Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma
    Oba, Atsushi
    Ban, Daisuke
    Kirimura, Susumu
    Akahoshi, Keiichi
    Mitsunori, Yusuke
    Matsumura, Satoshi
    Ochiai, Takanori
    Kudo, Atsushi
    Tanaka, Shinji
    Minoru, Tanabe
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2016, 23 (08) : 480 - 488
  • [7] Biomarker detection in pancreatic ductal adenocarcinoma
    Klett, H.
    Klose, M.
    Kowar, S.
    Bronsert, P.
    Kuesters, S.
    Werner, M.
    Christoph, P.
    Busch, H.
    Boerries, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S177 - S178
  • [8] Protein biomarker for pancreatic ductal adenocarcinoma
    Burki, Talha K.
    LANCET ONCOLOGY, 2017, 18 (09): : E511 - E511
  • [9] Evaluation of the Significance of Adjuvant Chemotherapy in Patients With Stage IA Pancreatic Ductal Adenocarcinoma
    Izumo, W.
    Higuchi, R.
    Yamamoto, M.
    PANCREAS, 2021, 50 (07) : 1068 - 1068
  • [10] Evaluation of the significance of adjuvant chemotherapy in patients with stage IA pancreatic ductal adenocarcinoma
    Izumo, Wataru
    Higuchi, Ryota
    Furukawa, Toru
    Yazawa, Takehisa
    Uemura, Shuichiro
    Matsunaga, Yutaro
    Shiihara, Masahiro
    Yamamoto, Masakazu
    PANCREATOLOGY, 2021, 21 (03) : 581 - 588
12345